Stephanie studied BSc. Chemical and Pharmaceutical Science at the University of Sunderland, graduating with Honours in 2007. During the course of her degree, she joined GlaxoSmithKline in Hertfordshire as an industrial placement student working in the Psychiatry Centre of Excellence for Drug Discovery to investigate pharmacokinetic properties of new-generation atypical antipsychotic drugs.
Following completion of her Bachelor’s degree, she received a Master’s degree in Drug Chemistry at Newcastle University with Distinction, followed by a PhD in Medicinal Chemistry funded by Cancer Research UK, under the supervision of Dr Celine Cano and Dr Ian Hardcastle within the Northern Institute of Cancer Research (NICR).
Stephanie rejoined the NICR in March 2013 as a Research Associate funded by the Medical Research Council (MRC), working towards the discovery of inhibitors of the kinase ERK5 for biomarker-driven clinical evaluation in cancer, in collaboration with Cancer Research Technology (CRT), the Babraham Institute and Astex Pharmaceuticals.
In August 2014 Stephanie moved to the Institute of Cancer Research (ICR), one of the world’s most influential cancer research organisations, joining the team of Professor Ian Collins. Stephanie joined the team as a Research Training Fellow to optimise inhibitors of inositol-requiring enzyme 1 (IRE-1), a dual kinase-endonuclease enzyme. Stephanie then became the leading chemist on new project to identify kinesin-like protein KIFC1 (HSET) inhibitors (hit-generation and lead-identification).
Stephanie went on to join the University of Wolverhampton in September 2016 as a lecturer in Pharmaceutical Chemistry and is presently involved in teaching on the MPharm, BSc Pharmaceutical Science, Faculty of Science and Engineering Foundation Year and MSc Pharmaceutical Science courses within the School of Pharmacy.
In her spare time, Stephanie enjoys participating in public engagement activities and acts as a STEM ambassador, encouraging young people to pursue careers in science.
Development of small-molecule inhibitors of kinases and kinesins for the treatment of cancer
Associate Member of the Royal Society of Chemistry
Myers, S.M., Bawn, R.H., Bisset, L.C., Blackburn, T.J., Cottyn, B., Molyneux, L., Wong, A.C., Cano, C., Clegg, W., Harrington, R.W., Leung, H., Rigoreau, L., Vidot, S., Golding, B.T., Griffin, R.J., Hammonds, T., Newell, D.R, Hardcastle, I.R., Screening and Hit Validation Studies for Extracellular Signal-Regulated Kinase 5 (ERK5) Inhibitors, ACS Comb. Sci. 2016, 18, 444-455.
Reuillon, T., Miller, D., Myers, S., Molyneux, L., Cano, C., Hardcastle, I., Rigoreau, L., Golding, B., Noble, M., Griffin, R. Pyrrolcarboxamide derivatives for the inhibition of ERK5, PCT Int. Appl. 2016, WO/2016/042341.
Myers, S.M., Collins, I., Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy, Future Medicinal Chemistry, 2016, 8, 463-489.
S. Myers, R. Bawn, T. Blackburn, L. Barrett, N. Martin, T. Reuillon, B. Golding, R. Griffin, T. Hammonds, I. Hardcastle, H. Leung, D. Newell, L. Rigoreau, A. Wong, C. Cano, Development of ERK5 inhibitors for anti-cancer therapy.
S. Myers, L. Barrett, R. Bawn, T. Blackburn, B. Cottyn, B.T. Golding, R.J. Griffin, T. Hammonds, H. Leung, N.C. Martin, D.R. Newell, L. Rigoreau, A. Wong, C. Cano and I.R. Hardcastle, Hit Validation of ERK5 Inhibitors: Expectations and Challenges.
S. Myers, B. Cottyn, R.J. Griffin, T. Hammonds, H. Leung, D.R Newell, L. Rigoreau, A. Wong, C. Cano and I.R. Hardcastle, The Development of 3-Cyanopyridines as ERK5 Inhibitors.
Other Poster Contributions: